Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MI-63 |
| Synonyms | |
| Therapy Description |
MI-63 is a small molecule, high-affinity, non-peptide inhibitor of MDM2 and in cancer cells with wild type Tp53, MI-63 treatment results in reactivation of Tp53 (PMID: 19707204, PMID: 31189611). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MI-63 | MDM2 Inhibitor 23 | MI-63 is a small molecule, high-affinity, non-peptide inhibitor of MDM2 and in cancer cells with wild type Tp53, MI-63 treatment results in reactivation of Tp53 (PMID: 19707204, PMID: 31189611). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 mutant | neuroblastoma | resistant | MI-63 | Preclinical | Actionable | In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357). | 21725357 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|